SQ makes a price jump of $18 after each big drop, according to its trend. On November 6, SQ is expected to report high earnings. As previously mentioned, we should expect the pattern to play out once again.
FATE's an outstanding buy. It displays a relatively stable graph of constant income throughout the period. Unlike most pharmaceutical shares, FATE does not crash hard but takes a short break when confronted with unexpected and expected bearish trends With the expectation of potentially not slipping anywhere below, FATE has built up-dip resistance of about $14....
SQ has alot of potential. While it follows a trend of falling and then eventually regaining lost earnings, if SQ can manage to break Bulls at above $67.00, I can see the potential of it eventually rallying to $70.00 but there is also the potential of it reaching all the way back up to $80.00+. Though SQ has a resistance of $64.00-$66.00. Each Milestone SQ has...
